[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100365920":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":24,"id":56,"slug":24,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":24,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":24,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":39,"whyStopped":24,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"VA Connecticut Healthcare System","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intranasal insulin","EXPERIMENTAL","Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).",[13],"Drug: Intranasal insulin",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo","Subjects in this arm will receive placebo.",[18],"Drug: Placebo",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Subjects in this arm will receive intranasal insulin (80 IU per day).",[9],null,{"type":21,"name":15,"description":16,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"affiliation":5,"role":30},"Gihyun Yoon, MD","PRINCIPAL_INVESTIGATOR",[32],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","(203) 932-5711","7421","gihyun.yoon@yale.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","West Haven","Connecticut","06516","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-72.94705,41.27065,{"lat":49,"lon":48},[52],{"name":29,"role":33,"phone":53,"phoneExt":35,"email":36},"203-932-5711",{"type":30,"investigatorFullName":29,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Principal Investigator","100365920",false,"NCT04044534","Intranasal Insulin for Posttraumatic Stress Disorder","Intranasal Insulin for Treating Posttraumatic Stress Disorder","Inclusion Criteria:\n\n* Male or female, 21-65 years old\n* Current PTSD\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Unstable medical condition, clinically determined by a physician\n* Diabetes requiring insulin or oral hypoglycemic agents\n* Moderate-severe traumatic brain injury\n* Current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months\n* Current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3 months\n* Changes in doses of psychotropic medications in the past 4 weeks\n* Initiation of individual therapy or counseling in the past 4 weeks\n* Imminent suicidal or homicidal risk\n* Contraindication to Insulin\n* History of claustrophobia\n* Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI safety screening questionnaire","ALL","21 Years","65 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","To evaluate if intranasal insulin is effective in reducing PTSD symptoms.",[73],"PTSD",[9,73],"2025-09-15",{"date":77,"type":78},"2025-09-16","ACTUAL",{"date":80,"type":78},"2024-10-31",{"date":82,"type":67},"2026-05-31",{"name":5,"class":6},1]